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In addition to acquired immunodeficiency syndrome
(AIDS), persons infected with human immunodeficiency
virus often develop cutaneous manifestations, including
severe psoriasis. In previous studies, we have established
that psoriatic fibroblasts and erythrocytes obtained from
psoriatic patients exhibit decreased levels of cyclic adeno-
sine monophosphate (cAMP) dependent protein kinase
(PKA) activity and of 8-azido-[32P]cAMP binding to the
RI and RII regulatory subunits of PKA. Because treatment
of patients with peptide T (an octapeptide sequence
found in the human immunodeficiency virus envelope
glycoprotein gp120) has been observed to result in an
improvement in the psoriatic condition, studies were
initiated to determine if peptide T and gp120 protein
treatment of normal and psoriatic human fibroblasts
resulted in any changes in PKA. Exposure of psoriatic
fibroblasts to peptide T resulted in a time (4 h to 6 d)
and dose (10–14–10–8 M) dependent increase in the levels of
8-azido-[32P]cAMP binding to the RI and RII regulatory
Psoriasis is an erythematous, papulosquamous disease charac-terized by benign hyperproliferation (Weinstein and Frost,1958), inflammation (Braveman and Yen, 1977), anddefective epidermal differentiation (Boden et al, 1978).This disease is not limited to the skin, because it can also
affect joints, blood vessels, and perhaps other organs (Krueger, 1994).
Psoriasis affects 2–4% of people, and an increased incidence of psoriasis
has been reported in human immunodeficiency virus (HIV) infected
patients (Johnson et al, 1985; Duvic et al, 1987a; Duvic, 1995). Whereas
the pathogenesis of the disease remains unclear, a viral cause has been
postulated for some patients (Dalen et al, 1983; Bjerke et al, 1983;
Dieyel et al, 1987). Observations that treatment of HIV patients having
psoriatic lesions with either zidovudin or peptide T (an octapeptide
homologous to the segment of the gp120 HIV envelope glycoprotein
that is essential for attachment to CD4 receptors) resulted in an
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subunits of PKA, along with a corresponding increase
in PKA activity. Peptide T exhibited a biphasic dose
dependent response, with maximal effects on PKA noted
at 10–12 M peptide T. Treatment of normal human
fibroblasts with peptide T did not result in any change
in PKA levels. Conversely, treatment of normal human
fibroblasts for 18 h with gp120 protein (10–13 M) resulted in
a significant decrease in the levels of 8-azido-[32P]cAMP
binding to RI and RII and in PKA activity. The presence
of peptide T blocked this effect of the gp120 protein.
These results indicate that peptide T and gp120 protein
may inversely alter the intracellular levels of 8-azido-
[32P]cAMP binding to RI and RII, and of PKA activity
in susceptible cells. These observed changes in the cyclic
AMP-PKA signaling pathway, a biochemical marker for
psoriasis, may offer some mechanistic insight into the
noted beneficial effects of peptide T treatment, including
an improvement in psoriatic lesions. Key words: cAMP
dependent protein kinases/gp120 protein/peptide T/psoriasis.
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improvement of the psoriatic lesions are of interest (Wetterberg et al,
1987; Duvic et al, 1987b, 1994; Bridge et al, 1989; Townsend et al,
1995). More recent studies performed on psoriatic patients confirmed
the beneficial effects of peptide T on this disease (Marcusson et al,
1989, 1991; Marcusson and Wetterberg, 1989; Farber et al, 1991;
Delfino et al, 1992; Talme et al, 1995).
Previous studies have established that cyclic adeonsine monophos-
phate (cAMP) dependent protein kinase (PKA) activity, as well as
8-azido-[32P]cAMP binding to the RI and RII regulatory subunits of
PKA, is decreased in cells from psoriatic patients compared with cells
from normal patients (Evain-Brion et al, 1986; Raynaud et al, 1989).
Because peptide T appears to have a beneficial response in the treatment
of psoriasis, studies were initiated to determine if peptide T and gp120
protein treatment of fibroblasts prepared from normal and psoriatic
patients might differentially alter PKA in these cells in culture. In this
study evidence is presented that treatment of psoriatic fibroblasts with
peptide T increased PKA activity and cyclic AMP binding to the
regulatory subunits toward normal levels. In addition, exposure of
normal human fibroblasts to the gp120 HIV envelope protein caused
a decrease in both PKA activity and cyclic AMP binding to RI and
RII toward levels found in psoriatic fibroblasts. These results suggest
that exposure of cells to gp120 protein and peptide T inversely
modulates the cyclic AMP-PKA signaling pathway in normal and
psoriatic cells, respectively.
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MATERIALS AND METHODS
Materials Kemptide, cyclic AMP, trypsin (2x crystallized), collagenase (type
II-5), MES [2(N-Morpholinoethane sulfonic acid)], and MOPS [3(N-Morpho-
linopropane sulfonic acid)] were purchased from Sigma (St. Louis, MO).
Pepstatin, antipain, chymostatin, leupeptin, and soybean trypsin inhibitor were
obtained from Boehringer (Indianapolis, IN). HAM’s F-12 media, glutamine,
trypsin 20X, and penicillin-streptomycin were from GIBCO (Gaithersburg,
MD), fetal calf serum was from Flow Laboratories (McLean, VA), 8-azido
adenosine 39,59-[32P]cyclic AMP was from ICN Pharmaceuticals (Costa Mesa,
CA), and (γ-32P) adenosine triphosphate (3000 Ci per mmol) was from Dupont-
New England Nuclear (Boston, MA). D-Ala peptide T NH2 (D-ala
1-ser-thr-
thr-thr-asn-tyr-thr-amide) and peptide TTNdYT were generously provided by
Dr. Candace Pert (Peptide Design, Gaithersburg, MD). Peptide T also was
purchased from Peninsula Laboratories (Belmont, CA). The gp120 protein was
kindly provided by Drs. Stephan W. Pyle and Larry O. Arthur (AIDS
Vaccine Program, Program Resources, NCI-Frederick Cancer Research Facility,
Frederick, MD) under contract #N01-CO-74102. The anti-CD4 receptor
antibody OKT4 was from Orthopharmaceuticals (San Diego, CA).
Cell culture Human fibroblasts were isolated from four normal and six
untreated psoriatic adult patients by enzymatic digestion of small pieces (3 mm)
of dermis from skin biopsies taken from nonlesional and lesional tissue as
described previously (Raynaud et al, 1987). Cells were grown in HAM’s F12
medium containing 10% fetal calf serum, penicillin (50 U per ml), and
streptomycin (50 mg per ml) in a 5% CO2 humidified atmosphere at 37°C.
The culture medium was changed every 3 d. In these studies the cells were
used from the fourth passage through the tenth passage in culture. Where
indicated, peptide T was added every 24 h during the time-course studies.
Preparation of cellular fractions All procedures were performed at 4°C
under conditions described by Ally et al (1988). Cells (1 3 107 cells per dish)
were washed three times with ice cold buffer A (0.25 M sucrose, 2 mM MgCl2,
1 mM CaCl2, 10 mM KCl, 20 mM Tris-HCl, pH 7.5, 0.1 mM pepstatin,
0.1 mM antipain, 0.1 mM chymostatin, 0.2 mM leupeptin, 0.4 mg aprotinin
per ml, and 0.5 mg soybean trypsin inhibitor per ml), harvested from the dish
by scraping, suspended in 3 ml buffer A, and disrupted with a Dounce
homogenizer (70 strokes). The homogenate was centrifuged at 800 3 g for
10 min to remove nuclei and any unbroken cells. The 800 3 g supernatant
was centrifuged at 10,000 3 g for 15 min, and the resulting pellet was retained
as the crude membrane fraction. The 10,000 3 g supernatant was centrifuged
at 100,000 3 g for 60 min and the resulting supernatant was used as the
cytosolic fraction for photoaffinity labeling experiments and for protein kinase
activity determinations.
Photoaffinity labeling with 8-azido-[32P]cAMP Photoaffinity labeling of
the RI and RII regulatory subunits of PKA was performed by the method of
Walter et al (1977, 1983), and as described in detail by Tournier et al (1995).
The samples were subjected to 12% polyacrylamide slab gel electrophoresis in
the presence of sodium dodecyl sulfate (Laemmli, 1970). The gels were dried
and autoradiography was carried out at –80°C using Kodak XAR film. Where
indicated the autoradiographs were scanned with a microdensitometer, and the
peak heights of the densitometric scans were found to be proportional to the
radioactivity found in the corresponding peaks. The values of RI and RII were
calculated by integrating the areas under the curves obtained from the
microdensitometric scans of the autoradiographs and substracting the nonspecific
labeling. Protein concentration was measured with the BCA (bicinchoninic
acid) Protein Assay Reagent from Pierce (Smith et al, 1985) using bovine serum
albumin as the standard.
Anion exchange chromatographic separation of PKA Cytosolic fractions
(2 ml containing about 2.5–4 mg protein) isolated from the indicated cell
populations were applied to Mono Q columns (5 3 50 mm, Pharmacia, LKB),
previously equilibrated with buffer B (20 mM potassium phosphate buffer,
pH 6.8, 1 mM ethylenediamine tetraacetic acid, and 2 mM 2-mercaptoethanol).
The columns then were washed with 5 ml of buffer B and eluted with a linear
gradient of 0–0.5 M NaCl in buffer B. Fractions of 1 ml were collected.
Protein kinase assay PKA activity was measured in each Mono Q column
fraction by the method of Roskoski (1983); using Kemptide (a highly specific
substrate of PKA) as the phosphate acceptor. Ten microliters of each fraction
were used to catalyze the transfer of 32P from [γ-32P] adenosine triphosphate
(5 nmol, 8 3 105 cpm) to 5 µg of Kemptide as described in detail by Raynaud
et al (1997). The level of PKA activity was calculated by subtracting the amount
of activity measured in the absence of cAMP from the level of activity measured
in the presence of 1 µM cAMP.
Table I. Quantitation of 8-azido-[32P]cyclic AMP binding to
the RI and RII regulatory subunits of PKA in the cytosolic
and particulate fractions of fibroblasts prepared from normal
and psoriatic subjectsa
Cytosol Particulate
Subject RIb RIIb RIb RIIb
Normal
1 1190 453 517 150
2 1350 500 684 245
3 1090 375 519 162
4 1280 422 620 179
Mean 6 SEM 1227 6 65 437 6 30 585 6 47 184 6 24
Psoriatic
5 Involved 532 58 85 undetectable
6 Involved 610 83 149 undetectable
7 Involved 625 160 263 68
8 Involved 560 96 140 undetectable
9 Involved 1050 330 350 127
10 Involved 785 128 252 102
Mean 6 SEM 693 6 87 142 6 44 208 6 43 49 6 25
5 Uninvolved 680 105 190 60
7 Uninvolved 990 310 328 165
8 Uninvolved 820 185 309 105
10 Uninvolved 1000 290 384 140
Mean 6 SEM 872 6 88 222 6 55 302 6 47 117 6 26
aCultured fibroblasts were established from skin biopsies obtained from four normal
subjects and from the involved lesional skin of six psoriatic subjects. Cells were prepared
from the uninvolved skin of only four of the psoriatic subjects, as indicated. Cytosolic and
particulate fractions were prepared from normal and psoriatic human fibroblast cell
populations in culture as described in Materials and Methods. One hundred micrograms
protein from each fraction was photoaffinity labeled with 1 µM 8-azido-[32P]cAMP in
the presence and absence of 100 µM cAMP and then analyzed by sodium dodecyl sulfate
polyacrylamide gel electrophoresis as described. The amount of 8-azido-[32P]cAMP bound
to RI and RII subunits was quantitated by scanning of the gel with an AMBIS scanner.
Any nonspecific labeling (noted in the presence of added cAMP) was substracted and the
levels of RI and RII were calculated based on the specific activity of 8-azido-[32P]cAMP.
Results are the mean of duplicate determinations and are expressed as fentomoles bound
per mg protein of the cell fraction. Values expressed as mean 6 SEM are of the duplicate
determinations of the cell fractions prepared from all of the normal and psoriatic
patients indicated.
bfmol 8-azido-[32P] cAMP bound per mg protein.
RESULTS
Treatment of psoriatic fibroblasts with peptide T increases PKA
activities The levels of cyclic AMP binding to the RI and RII
regulatory subunits of PKA present in the soluble and membrane
fractions prepared from normal and psoriatic human fibroblasts were
determined by photoaffinity labeling with 8-azido-[32P]cAMP. As
presented in Table I, and in agreement with previous studies (Evain-
Brion et al, 1986; Raynaud et al, 1987), the level of cAMP binding to
RI and RII present in fibroblasts prepared from five of the six psoriatic
subjects was significantly decreased relative to that of normal fibroblasts.
Fibroblasts prepared from the sixth psoriatic patient (subject 9) also
exhibited lower levels of cAMP binding compared with normal
fibroblasts, although the decrease was less significant. Similar results
were obtained with cells prepared from both the involved and the
uninvolved skin of the psoriatic subjects. Because the results of
preliminary studies indicated that similar effects of peptide T were
noted with psoriatic cells prepared from both involved and uninvolved
skin, all further studies to characterize the effects of peptide T and
gp120 protein on PKA in psoriatic cells were carried out only with
cells prepared from involved skin. To determine if peptide T treatment
might influence PKA in psoriatic cells, psoriatic fibroblasts initially
were exposed to 10–8 M peptide T for the time periods indicated
(Fig 1). Quantitation of autoradiographs by densitometer scanning
revealed a progressive increase in 8-azido-[32P] cAMP binding to RI
and RII through 4 d of treatment (Fig 1A). A lesser increase in cAMP
binding could be observed within 4 h of exposure to peptide T
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Figure 1. Treatment of psoriatic fibroblasts with peptide T results in a
time dependent increase in 8-azido-[32P]cAMP binding to the RI and
RII regulatory subunits. Cells were treated with 10–8 M peptide T for the
times indicated (up to 6 d) prior to harvesting the cells and preparation of
cytosol. Cytosolic preparations (100 µg) were photoaffinity labeled with 8-azido-
[32P]cAMP as described in Materials and Methods. The amount of 8-azido-
[32P]cAMP bound to the RI and RII subunits was quantitated by densitometric
scanning of the radioautograph of the gel, and the results expressed as the relative
increase in densitometric units of 8-azido-[32P]cAMP binding determined in
treated cells relative to untreated cells. Arrows denote times (every 24 h) that
peptide T was added to the cells. In (A), cells were harvested 24 h after the
last indicated treatment with peptide T. In (B), cells were harvested at the
indicated times following treatment with peptide T. The results presented are
expressed as the mean 6 SD of three experiments carried out with primary
cultures obtained from three psoriatic patients.
(Fig 1B). Treatment of psoriatic cells for 18 h with increasing
concentrations of peptide T yielded a biphasic dose response curve,
with optimal stimulation of 8-azido [32P]cAMP binding to the regu-
latory subunits noted with 10–12 M peptide T (Fig 2). Peptide T
exhibited a biologic response (i.e., enhanced cAMP binding) at
concentrations as low as 10–14 M (Fig 2C). Treatment of these cells
with the less biologically active peptide TTNdYT also resulted in a
slight increase in cAMP binding relative to the response noted with
active peptide T (Fig 2B). The RII regulatory subunit appeared to be
more responsive to peptide T because exposure of psoriatic fibroblasts
to 10–12 M peptide T resulted in a 6-fold increase in cAMP binding
to RII and only a 2-fold increase in binding to RI. Similar, though
less pronounced, increases in cAMP binding to RI and RII present in
the particulate fraction were also observed following exposure of
psoriatic fibroblasts to peptide T (unpublished data). Further, treatment
of normal fibroblasts with peptide T showed little or no effect on
the levels of 8-azido-[32P]cAMP binding to the regulatory subunits
(unpublished data). This apparently is due to the fact that normal
fibroblasts already show higher levels of cAMP binding as presented
in Table I.
Next, we examined if peptide T treatment of psoriatic cells also
resulted in increased levels of PKA phosphotransferase activity. Figure 3
shows the profile of PKA activity after Mono Q chromatographic
fractionation of cytosols prepared from psoriatic fibroblasts before and
after treatment with 10–12 M peptide T for 18 h. Two PKA activity
peaks eluted from the columns with increasing NaCl concentrations.
The first peak (maximal activity at fraction 10 eluted at or about 0.1 M
NaCl) corresponded to type I PKA, whereas the second peak (maximal
activity at fraction 27 eluted at or about 0.3 M NaCl) corresponded
to type II PKA. Elevated levels of PKA activity were noted in both
major activity peaks observed with the cytosol prepared from cells
exposed to peptide T.
Treatment of normal fibroblasts with gp120 protein decreases
PKA activities Because the gp120 HIV envelope glycoprotein has
been reported to have biologic effects that can be blocked by peptide
T (Brenneman et al, 1988b; Buzy et al, 1992; Hill et al, 1993), studies
were initiated to determine if exposure of human fibroblasts to gp120
had any effect on PKA. The PKA regulatory subunits RI and RII
present in cytosols prepared from normal human fibroblasts incubated
in the presence and absence of gp120 and peptide T as indicated, were
analyzed by photoaffinity labeling with 8-azido-[32P]cAMP (Fig 4).
Figure 2. Treatment of psoriatic fibroblasts with increasing concentra-
tions of peptide T results in a progressive increase in 8-azido-[32P]cAMP
binding to the RI and RII regulatory subunits. Psoriatic human fibroblasts
were treated with the indicated peptide concentrations for 18 h prior to
preparation of cytosolic fractions. (A) Autoradiograph showing the photo-
activated incorporation of 8-azido-[32P]cAMP into the cytosolic cAMP binding
proteins (RI and RII) analyzed by sodium dodecyl sulfate polyacrylamide slab
gel electrophoresis as described in Materials and Methods. (B, C) The amount of
8-azido-[32P]cAMP bound to the RI and RII subunits was quantitated by
densitometric scanning of radioautographs, and the results are expressed as the
relative increase in densitometric units of 8-azido-[32P]cAMP binding
determined in cells treated with the indicated concentrations of less active
TTNdYT (B) and peptide T (C) relative to untreated controls. The results
presented are expressed as the mean 6 SD of three experiments carried out
with primary cultures prepared from three psoriatic patients.
Whereas treatment of normal fibroblasts for 18 h with 10–12 M gp120
protein had no appreciable effect, a distinct decrease in the ability of
the regulatory subunits to bind the cAMP analog was observed in cells
treated with 10–13 M and 10–14 M gp120 (Fig 4, lanes 3–5). This
decrease was more pronounced with the type II (RII) subunit. When
cells were incubated with 10–13 M gp120 along with the OKT4
antibody (directed against the CD4 receptor), the presence of the CD4
receptor antibody was only partially effective in blocking the gp120
response to decrease 8-azido-[32P] cAMP binding to RI and RII (lane
6); however, the presence of peptide T completely blocked the ability
of gp120 protein to decrease cAMP analog binding to the regulatory
subunits (lanes 7 and 8). When added alone, peptide T had no
significant effect on the ability of RI and RII to bind the cAMP analog
in normal fibroblasts (lane 2).
To determine if the decrease in cyclic AMP analog binding to RI
and RII in response to gp120 protein correlated with a change in PKA
phosphotransferase activity, soluble extracts prepared from normal
fibroblasts incubated in the presence and absence of 10–13 M gp120
protein for 18 h were fractionated by Mono Q chromatography under
conditions that separate the type I and type II PKA holoenzymes
(Fig 5). The PKA activities corresponding to the first (maximal activity
at fraction 10 eluted at about 0.1 M NaCl) and second (maximal
activity at fraction 27 eluted at about 0.3 M NaCl) activity peaks were
both decreased in normal fibroblasts treated with gp120 protein.
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Figure 3. Peptide T treatment of psoriatic fibroblasts results in increased
levels of PKA activities. Cytosolic fractions were prepared from untreated
psoriatic fibroblasts (s) and from psoriatic fibroblasts treated with 10–12 M
peptide T for 18 h (d). The cytosolic fractions (4 mg protein) were applied to
a Mono Q column and chromatographed as described under Materials and
Methods. The results are given as cpm [32P] incorporated per min per 10 µl
aliquot after subtracting the amount of activity measured in the absence of
cAMP from the amount of activity measured in the presence of cAMP. Results
are expressed as the mean 6 SEM of two separate experiments run with
duplicate determinations of each column fraction. Similar activity profiles were
obtained in a second set of experiments with cells prepared from a different
psoriatic subject.
DISCUSSION
Peptide T is a synthetic octapeptide designed to correspond to an
amino acid sequence within the HIV envelope protein gp120 (Pert
et al, 1986). The viral envelope glycoprotein gp120 has been shown
to bind to CD4 receptors on human helper cells (Ruff et al, 1987a;
Brenneman et al, 1988a), and synthetic peptide T has been proposed
to block virus and gp120 binding at the CD4 receptor to inhibit HIV
infection of these cells (Ruff et al, 1987a). In addition, peptide T has
been reported to inhibit neuroneal cell death induced by treatment of
hippocampal neurons with gp120 (Brenneman et al, 1988a). In clinical
trials, an unexpected observation was that peptide T treatment of AIDS
patients with coexisting psoriasis resulted in clearing of the psoriatic
lesions (Duvic et al, 1987a,b; Wetterberg et al, 1987; Marcusson et al,
1989). Administration of peptide T to HIV negative psoriasis patients
also resulted in improvement in the psoriatic lesions of these patients
(Marcusson and Wetterberg, 1989; Farber et al, 1991; Marcusson et al,
1991; Delfino et al, 1992; Talme et al, 1995).
Whereas peptide T appears to have beneficial effects in the treatment
of psoriasis, little is known concerning the mechanism of peptide T
action in treating this disease. Others have suggested that peptide T
might block the CD4 receptor to prevent penetration of a putative
psoriasis-causing virus (Bjerke et al, 1983; Johansson et al, 1993), or
that there might be interactions between peptide T, vasoactive intestinal
polypeptide (VIP), somatostatin, and epidermal growth factor to
regulate cell growth (Johansson et al, 1993). It has also been suggested
that peptide T may affect the synthesis of somatostatin (Talme et al,
1994).
Cyclic AMP has been identified as an important regulatory com-
ponent in signal transduction to modulate numerous cellular functions,
including growth and differentiation. PKA appears to be largely, if not
solely, responsible for mediating the biologic effects of cyclic AMP
(Greengard, 1978). There are two major forms of PKA (types I and
II) that differ in the nature of their cyclic AMP binding regulatory
subunits (RI and RII). Previously, we have demonstrated a deficiency
Figure 4. Treatment of normal fibroblasts with gp120 protein causes a
decrease in 8-azido-[32P]cAMP binding to the RI and RII regulatory
subunits. Normal human fibroblasts were treated for 18 h with the given
concentrations of gp120 protein in the presence and absence of peptide T and
OKT4 antibody, as indicated, prior to preparation of cytosolic fractions. (A)
Autoradiograph showing the photoactivated binding of 8-azido-[32P]cAMP to
the cytosolic cAMP binding proteins RI and RII analyzed by sodium dodecyl
sulfate polyacrylamide slab gel electrophoresis as described in Materials and
Methods. (B) Relative levels of the RI and RII regulatory subunits following
treatment with the indicated concentrations of gp120 protein and peptide T as
determined by densitometric scanning of the autoradiograph. Values are given
relative to the level of RI (set at 100) found in untreated control fibroblasts.
Lane 1, untreated control; lane 2, 10–12 M peptide T; lane 3, 10–12 M gp120
protein; lane 4, 10–13 M gp120 protein; lane 5, 10–14 M gp120 protein; lane 6,
10–13 M gp120 protein 1 (0.1 mg per ml) OKT4 antibody; lane 7, 10–13 M
gp120 protein 1 10–10 M peptide T; lane 8, 10–13 M gp120 protein 1
10–12 M peptide T. The results are expressed as the mean 6 SD of three
experiments carried out with primary cells from three normal subjects.
in the PKA in psoriasis (Evain-Brion et al, 1986). This defect in PKA
is expressed in fibroblasts and in red blood cells isolated from psoriatic
patients (Evain-Brion et al, 1986; Raynaud et al, 1989), and is
characterized by a decrease in 8-azido-[32P]cAMP binding to RI and
RII, and by a decrease in PKA activities. Furthermore, it was found
that the low level of 8-azido-[32P]cAMP labeling observed in psoriatic
fibroblasts is due to a decreased ability of the regulatory subunit to
bind the cyclic AMP analog, and not to a decrease in the amount of
the subunit protein present in psoriatic cells (Tournier et al, 1995).
Similar to the observations cited above for peptide T, retinoic acid
derivatives have been used with some success in the therapeutic
treatment of psoriasis. We have shown that exposure of psoriatic cells
to retinoic acid induces an increase in PKA activity, and an increase
in the binding of 8-azido-[32P]cAMP to the regulatory subunits
(Raynaud et al, 1987, 1993). In addition, treatment of psoriatic patients
with synthetic retinoids (etretinate and acitretin) resulted in an elevation
in 8-azido-[32P]cAMP binding in erythrocytes isolated from these
subjects (Raynaud et al, 1989, 1993). Of related interest is a report
that demonstrated that retinoic acid treatment of six HIV infected
individuals resulted in inhibition of HIV associated apoptosis of
peripheral blood mononuclear cells (Yang et al, 1995). Thus, studies
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Figure 5. Normal fibroblasts treated with gp120 protein exhibit
decreased levels of PKA activities. Cytosolic fractions were prepared from
untreated normal fibroblasts (s) and from normal fibroblasts treated with
10–13 M gp120 protein for 18 h (d). Two and a half milligrams protein of the
cytosolic fractions were applied to a Mono Q column and chromatographed as
described in Materials and Methods. PKA activities in the collected fractions were
assayed, calculated, and presented as described in the legend to Fig 3. Similar
activity profiles were obtained in a second set of experiments with cells prepared
from a different normal subject.
were carried out to determine if exposure of psoriatic cells to peptide
T might also have an effect on the cyclic AMP signaling pathway.
Here we demonstrate that exposure of psoriatic fibroblasts to very
low (10–12 M to 10–14 M) concentrations of peptide T increased cyclic
AMP analog binding to RI and RII regulatory subunits, and also
elevated both type I and type II PKA phosphotransferase activities.
This concentration range of peptide T found to exert an effect on
PKA is in agreement with other biologic effects of this peptide (Ruff
et al, 1987; Brenneman et al, 1988a). Similar treatment of normal
fibroblasts with peptide T had little effect on PKA.
Because peptide T has been shown to block some of the biologic
effects of the gp120 HIV envelope protein (Brenneman et al, 1988a;
Buzy et al, 1992; Hill et al, 1993), studies were also carried out to
examine the possible effects of exposure of normal fibroblasts to gp120
protein on PKA. Unexpectedly, treatment of normal fibroblasts with
low (10–13 M to 10–15 M) concentrations of gp120 resulted in a
significant decrease in 8-azido-[32P]cAMP binding to RI and RII. The
effective concentration range noted for gp120 corresponds with the
biologic effects of the envelope protein on neuroneal cells (Brenneman
et al, 1988a, b). Exposure of normal fibroblasts to gp120 also caused a
decrease in PKA activity. The observed effects of gp120 protein on
PKA were completely blocked by peptide T.
The mechanism by which peptide T and gp120 act to alter PKA in
human fibroblasts remains to be determined. The less active peptide,
TTNdYT, which has been shown to be completely inactive in some
biologic assays (Brenneman et al, 1988a), was observed here to have
some effect on PKA. The OKT4 antibody (directed against the CD4
receptor) has been shown to inhibit gp120 binding to the CD4 receptor
(Ruff et al, 1987); however, our results indicate that this antibody only
partially inhibited the effect of gp120 on PKA. Taken together, these
results raise the possibility that the observed effects of peptide T and
gp120 protein on PKA may be mediated by interaction with a receptor
other than CD4.
It has previously been suggested that several fibroblastic and neural
cell lines may be infected by HIV through a receptor other than CD4
(Tateno et al, 1989; Harouse et al, 1989), and Fantini et al (1993) have
suggested that galactosylceramide might act as an alternative receptor
for cells that lack the CD4 receptor. Another possibility would be a
VIP-like receptor, because VIP has been noted to have pentapeptide
sequence homology (VIP 7–11; TDNYT) with both peptide T and
gp120 (Brenneman et al, 1988a, b). More recently, several laboratories
have identified an essential cell-surface ‘‘coreceptor’’ CCR-5 (cysteine-
cysteine chemokine receptor-5) that is required for the HIV strains
involved in the early stages of infection (Alkhatib et al, 1996; Deng
et al, 1996; Dragic et al, 1996). Others have also reported that CCR-
5 acts as a fusion cofactor, and that some strains of HIV-1 can use
other chemokine receptors (CCR-3 and CCR-2b) as fusion cofactors
(Choe et al, 1996; Daranz et al, 1996). These receptors are members
of a family of G-protein coupled chemokine receptors with seven
transmembrane domains (Weiss, 1996). Conceivably, such receptors
with seven transmembrane domains could be involved in mediating
some of the cell signaling and biologic effects of peptide T and gp120
protein, including the changes noted with PKA.
In conclusion, we have presented evidence that indicates that
treatment of normal human fibroblasts with gp120 protein decreased
PKA activity and cyclic AMP binding to the RI and RII regulatory
subunits to levels found in psoriatic fibroblasts. Conversely, exposure
of psoriatic fibroblasts to peptide T restored cyclic AMP binding and
PKA activity toward normal levels. The mechanism(s) by which
peptide T and gp120 protein act to modulate PKA, and perhaps other
signaling pathways, remains to be determined. One possibility is that
these factors could act to alter the oxidative regulation of PKA.
Recently, we have reported that changes in the generation and/or
scavenging of oxygen free radicals may be an important regulatory
parameter of PKA, and that an altered oxidative state may be involved
in mediating the decrease in PKA activity and cyclic AMP binding
noted in cells from psoriatic subjects (Raynaud et al, 1997). Elucidation
of the mechanism by which peptide T and gp120 protein can act to
alter PKA is important to a better understanding of their downstream
signaling, as well as to an increased understanding of the pathogenesis
of psoriasis.
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